<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02385240</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-NY-14-022</org_study_id>
    <nct_id>NCT02385240</nct_id>
  </id_info>
  <brief_title>Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Padagis LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Padagis LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare safety and efficacy of Perrigo's rosacea drug product compared to an FDA approved&#xD;
      rosacea drug product in the treatment of facial erythema of rosacea.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects With Composite Success</measure>
    <time_frame>Day 15 at hour 6</time_frame>
    <description>2-grade improvement on both the Clinician's Erythema Assessment (CEA) and the Patient Self Assessment (PSA) scales</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With Composite Success</measure>
    <time_frame>Day 15 at hour 3</time_frame>
    <description>2-grade improvement on both the Clinician's Erythema Assessment (CEA) and the Patient Self Assessment (PSA) scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With Composite Success</measure>
    <time_frame>Day 15 at hour 9</time_frame>
    <description>2-grade improvement on both the Clinician's Erythema Assessment (CEA) and the Patient Self Assessment (PSA) scales</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">552</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Test product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brimonidine Topical Gel, 0.33 percent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Brimonidine Topical Gel, 0.33 percent (Reference)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine Topical Gel, 0.33 percent (Perrigo)</intervention_name>
    <arm_group_label>Test product</arm_group_label>
    <other_name>Perrigo product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine Topical Gel, 0.33 percent (Reference)</intervention_name>
    <arm_group_label>Reference Product</arm_group_label>
    <other_name>Reference Listed Drug Product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo gel</intervention_name>
    <arm_group_label>Placebo gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide IRB approved written informed consent/assent.&#xD;
&#xD;
          2. Male or non-pregnant female, ≥ 18 years of age.&#xD;
&#xD;
          3. Diagnosis of rosacea with moderate to severe erythema on the face defined as: a score&#xD;
             of ≥ 3 on the Clinician's Erythema Assessment (CEA) and a score of ≥ 3 on the&#xD;
             Patient's Self-Assessment (PSA) on Visit 1/Day 1 (Baseline) prior to the first&#xD;
             application of study medication at hour 0.&#xD;
&#xD;
          4. Willing and able to understand and comply with the requirements of the study.&#xD;
&#xD;
          5. Be in general good health and free from any clinically significant disease, other than&#xD;
             rosacea, that might interfere with the study evaluations.&#xD;
&#xD;
          6. Females of childbearing potential in addition to having a negative urine pregnancy&#xD;
             test, must be willing to use an acceptable form of birth control during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant, breast feeding, or planning a pregnancy within the study&#xD;
             participation period.&#xD;
&#xD;
          2. Presence of three (3) or more facial inflammatory lesions of rosacea.&#xD;
&#xD;
          3. Current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic&#xD;
             hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal&#xD;
             or hepatic impairment, scleroderma, Sjögren's syndrome or depression.&#xD;
&#xD;
          4. Other facial conditions that in the Investigator's opinion might interfere with a&#xD;
             rosacea diagnosis and/or assessment including but not limited to: acne conglobata,&#xD;
             acne fulminans, rhinophyma, facial pustulosis of the chin, peri-oral dermatitis,&#xD;
             demodicidosis, facial keratosis pilaris, seborrheic dermatitis, acute lupus&#xD;
             erythematosus, actinic keratosis, acne, dermatitis, psoriasis, squamous cell&#xD;
             carcinoma, eczema, acneiform eruptions caused by medications, steroid acne, steroid&#xD;
             folliculitis, or bacterial folliculitis .&#xD;
&#xD;
          5. Any uncontrolled, chronic or serious disease or medical condition that would prevent&#xD;
             participation in a clinical trial or, in the judgment of the Investigator, would put&#xD;
             the subject at undue risk or might confound the study assessments (such as planned&#xD;
             hospitalization during the study).&#xD;
&#xD;
          6. Subject consumes excessive alcohol, abuses drugs, or has a condition that could&#xD;
             compromise the subject's ability to comply with study requirements.&#xD;
&#xD;
          7. Excessive facial hair (such as beards, sideburns, moustaches, etc.) that would&#xD;
             interfere with diagnosis or assessment of rosacea.&#xD;
&#xD;
          8. History of hypersensitivity or allergy to any ingredient in the study medication.&#xD;
&#xD;
          9. Previous enrollment in this study.&#xD;
&#xD;
         10. Non-responders to prior treatment with topical brimonidine.&#xD;
&#xD;
         11. Currently using any product containing brimonidine tartrate or oxymetazoline.&#xD;
&#xD;
         12. Start or change of dose of hormonal treatments.&#xD;
&#xD;
         13. Start or change of dose of tricyclic or tetracyclic antidepressants, cardio&#xD;
             glycosides, beta blockers or calcium channel blockers or other anti-hypertensive&#xD;
             agents 3 months (90 days) prior to baseline or throughout the study. Use of such&#xD;
             therapy must remain constant during the study.&#xD;
&#xD;
         14. Current treatment with or start of any of the following class of drugs: monoamine&#xD;
             oxidase (MAO) inhibitors, barbiturates, opiates, sedatives, systemic anesthetics or&#xD;
             alpha-agonists, medicines for psychosis, medicines for hyperactivity&#xD;
&#xD;
         15. Use within 6 months (180 days) prior to baseline or during the study of oral retinoids&#xD;
             or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins&#xD;
             are allowed).&#xD;
&#xD;
         16. Use within 12 weeks (84 days) prior to baseline or during the study of systemic&#xD;
             immunomodulators&#xD;
&#xD;
         17. Use of medicated make-up throughout the study and/or significant change in the use of&#xD;
             consumer products within 4 weeks (28 days) of study entry and throughout the study.&#xD;
&#xD;
         18. Participation in any clinical study involving an investigational product or device in&#xD;
             the 4 weeks (28 days) prior to baseline or throughout the study.&#xD;
&#xD;
         19. Use of following topicals on the face within 14 days prior to baseline or during the&#xD;
             study of antibiotics and/or prescription anti-inflammatory agents including ophthalmic&#xD;
&#xD;
         20. Over the counter (OTC) topical anti-acne medications 7 days prior to baseline&#xD;
&#xD;
         21. Chronic, daily use of OTC anti-inflammatory medications for more than 7 days (does not&#xD;
             include low-dose aspirin for cardiac prophylaxis), 7 days prior to baseline and&#xD;
             throughout the study. Subjects may use acetaminophen for pain relief, as needed&#xD;
             throughout the study.&#xD;
&#xD;
         22. Use of tanning booths, sun lamps, sunbathing, phototherapy or excessive ultraviolet&#xD;
             (UV) exposure to the sun 7 days prior to baseline and throughout the study.&#xD;
&#xD;
         23. Use of Niacin ≥500 mg per day within 7 days of study start and throughout the study.&#xD;
&#xD;
         24. Use of topical astringents or abrasives within 2 days of study start and throughout&#xD;
             the study.&#xD;
&#xD;
         25. Use of antipruritics (including antihistamines), spa treatments or chlorine exposure&#xD;
             (swimming, etc.) within 24 hours of all study visits (Visit 1 through Visit 3).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 5, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <results_first_submitted>November 18, 2020</results_first_submitted>
  <results_first_submitted_qc>November 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 14, 2020</results_first_posted>
  <disposition_first_submitted>June 27, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>June 27, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 29, 2016</disposition_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brimonidine Tartrate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 19, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT02385240/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 19, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT02385240/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test Product</title>
          <description>Brimonidine Topical Gel, 0.33 percent&#xD;
Brimonidine Topical Gel, 0.33 percent (Perrigo)</description>
        </group>
        <group group_id="P2">
          <title>Reference Product</title>
          <description>Brimonidine Topical Gel, 0.33 percent (Reference)&#xD;
Brimonidine Topical Gel, 0.33 percent (Reference)</description>
        </group>
        <group group_id="P3">
          <title>Placebo Gel</title>
          <description>Placebo&#xD;
Placebo gel</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="184"/>
                <participants group_id="P3" count="185"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
                <participants group_id="P2" count="178"/>
                <participants group_id="P3" count="184"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test Product</title>
          <description>Brimonidine Topical Gel, 0.33 percent&#xD;
Brimonidine Topical Gel, 0.33 percent (Perrigo)</description>
        </group>
        <group group_id="B2">
          <title>Reference Product</title>
          <description>Brimonidine Topical Gel, 0.33 percent (Reference)&#xD;
Brimonidine Topical Gel, 0.33 percent (Reference)</description>
        </group>
        <group group_id="B3">
          <title>Placebo Gel</title>
          <description>Placebo&#xD;
Placebo gel</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="183"/>
            <count group_id="B2" value="184"/>
            <count group_id="B3" value="185"/>
            <count group_id="B4" value="552"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.4" spread="12.5"/>
                    <measurement group_id="B2" value="51.2" spread="13.29"/>
                    <measurement group_id="B3" value="50.9" spread="12.27"/>
                    <measurement group_id="B4" value="50.8" spread="12.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="137"/>
                    <measurement group_id="B4" value="431"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="167"/>
                    <measurement group_id="B4" value="481"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="181"/>
                    <measurement group_id="B4" value="546"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects With Composite Success</title>
        <description>2-grade improvement on both the Clinician's Erythema Assessment (CEA) and the Patient Self Assessment (PSA) scales</description>
        <time_frame>Day 15 at hour 6</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>Brimonidine Topical Gel, 0.33 percent&#xD;
Brimonidine Topical Gel, 0.33 percent (Perrigo)</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Brimonidine Topical Gel, 0.33 percent (Reference)&#xD;
Brimonidine Topical Gel, 0.33 percent (Reference)</description>
          </group>
          <group group_id="O3">
            <title>Placebo Gel</title>
            <description>Placebo&#xD;
Placebo gel</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Composite Success</title>
          <description>2-grade improvement on both the Clinician's Erythema Assessment (CEA) and the Patient Self Assessment (PSA) scales</description>
          <population>Per protocol population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>provides 85% power of success</non_inferiority_desc>
            <param_type>Equivalence ratio</param_type>
            <param_value>1.034</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.52</ci_lower_limit>
            <ci_upper_limit>10.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With Composite Success</title>
        <description>2-grade improvement on both the Clinician's Erythema Assessment (CEA) and the Patient Self Assessment (PSA) scales</description>
        <time_frame>Day 15 at hour 3</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>Brimonidine Topical Gel, 0.33 percent&#xD;
Brimonidine Topical Gel, 0.33 percent (Perrigo)</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Brimonidine Topical Gel, 0.33 percent (Reference)&#xD;
Brimonidine Topical Gel, 0.33 percent (Reference)</description>
          </group>
          <group group_id="O3">
            <title>Placebo Gel</title>
            <description>Placebo&#xD;
Placebo gel</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Composite Success</title>
          <description>2-grade improvement on both the Clinician's Erythema Assessment (CEA) and the Patient Self Assessment (PSA) scales</description>
          <population>Per protocol population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>provides 85% power of success</non_inferiority_desc>
            <param_type>Equivalence ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.94</ci_lower_limit>
            <ci_upper_limit>11.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With Composite Success</title>
        <description>2-grade improvement on both the Clinician's Erythema Assessment (CEA) and the Patient Self Assessment (PSA) scales</description>
        <time_frame>Day 15 at hour 9</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>Brimonidine Topical Gel, 0.33 percent&#xD;
Brimonidine Topical Gel, 0.33 percent (Perrigo)</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Brimonidine Topical Gel, 0.33 percent (Reference)&#xD;
Brimonidine Topical Gel, 0.33 percent (Reference)</description>
          </group>
          <group group_id="O3">
            <title>Placebo Gel</title>
            <description>Placebo&#xD;
Placebo gel</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Composite Success</title>
          <description>2-grade improvement on both the Clinician's Erythema Assessment (CEA) and the Patient Self Assessment (PSA) scales</description>
          <population>Per protocol population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>provides 85% power of success</non_inferiority_desc>
            <param_type>Equivalence ratio</param_type>
            <param_value>1.26</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.77</ci_lower_limit>
            <ci_upper_limit>15.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test Product</title>
          <description>Brimonidine Topical Gel, 0.33 percent&#xD;
Brimonidine Topical Gel, 0.33 percent (Perrigo)</description>
        </group>
        <group group_id="E2">
          <title>Reference Product</title>
          <description>Brimonidine Topical Gel, 0.33 percent (Reference)&#xD;
Brimonidine Topical Gel, 0.33 percent (Reference)</description>
        </group>
        <group group_id="E3">
          <title>Placebo Gel</title>
          <description>Placebo&#xD;
Placebo gel</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan Schwartz</name_or_title>
      <organization>Perrigo</organization>
      <phone>718-960-9900</phone>
      <email>jonathan.schwartz@perrigo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

